NASDAQ:MASI - Masimo Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $292.75
  • Forecasted Upside: 3.32 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$283.35
▲ +0.89 (0.32%)

This chart shows the closing price for MASI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Masimo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MASI

Analyst Price Target is $292.75
▲ +3.32% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Masimo in the last 3 months. The average price target is $292.75, with a high forecast of $310.00 and a low forecast of $276.00. The average price target represents a 3.32% upside from the last price of $283.35.

This chart shows the closing price for MASI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Masimo. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021Raymond JamesInitiated CoverageMarket PerformHigh
7/28/2021Piper SandlerBoost Price TargetOverweight$295.00 ➝ $300.00Low
4/29/2021Robert W. BairdReiterated RatingBuy$310.00Low
3/24/2021Piper SandlerLower Price TargetOverweight$310.00 ➝ $295.00Low
1/29/2021Raymond JamesBoost Price TargetOutperform$275.00 ➝ $285.00Low
1/14/2021Piper SandlerBoost Price TargetOverweight$280.00 ➝ $310.00High
10/28/2020Stifel NicolausBoost Price TargetBuy$255.00 ➝ $276.00High
10/28/2020Raymond JamesBoost Price TargetOutperform$250.00 ➝ $275.00High
10/28/2020Piper SandlerBoost Price TargetOverweight$250.00 ➝ $280.00High
10/6/2020Needham & Company LLCReiterated RatingHoldHigh
9/16/2020Raymond JamesReiterated RatingBuyLow
9/1/2020Robert W. BairdInitiated CoverageOutperform$260.00High
7/29/2020Stifel NicolausBoost Price TargetBuy$245.00 ➝ $255.00High
7/29/2020Raymond JamesBoost Price TargetOutperform$235.00 ➝ $250.00High
7/9/2020BTIG ResearchReiterated RatingHoldLow
6/26/2020Raymond JamesReiterated RatingBuyMedium
4/30/2020UBS GroupBoost Price TargetBuy$207.00 ➝ $245.00Medium
4/29/2020Stifel NicolausBoost Price TargetBuy$200.00 ➝ $245.00High
4/20/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
4/1/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/24/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/2/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$183.00High
2/20/2020Piper SandlerBoost Price Target$175.00 ➝ $201.00Low
2/20/2020Needham & Company LLCBoost Price TargetBuy$182.00 ➝ $201.00Medium
2/20/2020UBS GroupBoost Price TargetBuy$190.00 ➝ $207.00Medium
1/15/2020Piper SandlerReiterated RatingBuy$175.00Low
1/15/2020UBS GroupBoost Price TargetBuy$180.00 ➝ $190.00High
12/17/2019Piper Jaffray CompaniesReiterated RatingOverweight$161.00 ➝ $175.00Low
8/1/2019Stifel NicolausBoost Price TargetBuy$165.00 ➝ $170.00Medium
8/1/2019UBS GroupBoost Price TargetBuy$172.00 ➝ $180.00Medium
8/1/2019BTIG ResearchReiterated RatingHoldHigh
5/17/2019Stifel NicolausBoost Price TargetBuy$150.00 ➝ $160.00Low
5/17/2019Piper Jaffray CompaniesBoost Price Target$148.00 ➝ $160.00Low
5/7/2019UBS GroupBoost Price TargetBuy ➝ Buy$147.00 ➝ $160.00High
5/7/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$155.00 ➝ $158.00High
5/7/2019Piper Jaffray CompaniesBoost Price TargetOverweight$140.00 ➝ $148.00High
4/16/2019BTIG ResearchDowngradeBuy ➝ Neutral$134.50High
4/9/2019Needham & Company LLCReiterated RatingBuyLow
3/13/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$148.00 ➝ $155.00Medium
2/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$140.00High
2/1/2019Needham & Company LLCReiterated RatingBuy$139.00Low
12/19/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$120.00Medium
11/27/2018UBS GroupInitiated CoverageBuy$137.00High
11/1/2018Piper Jaffray CompaniesBoost Price TargetNeutral$120.00High
10/2/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$112.00 ➝ $145.00Low
9/14/2018Needham & Company LLCInitiated CoverageBuy ➝ BuyHigh
8/2/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$108.00 ➝ $112.00High
5/3/2018BTIG ResearchReiterated RatingBuy$100.00High
5/2/2018Piper Jaffray CompaniesBoost Price TargetNeutral$94.00High
3/9/2018BarclaysInitiated CoverageOverweight ➝ Overweight$97.00Medium
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$91.00High
11/3/2017Stifel NicolausReiterated RatingBuy$108.00N/A
8/14/2017BTIG ResearchUpgradeNeutral ➝ Buy$100.00Medium
8/3/2017Stifel NicolausReiterated RatingBuy$105.00 ➝ $108.00High
7/19/2017Roth CapitalBoost Price TargetBuy$96.00 ➝ $105.00Low
7/10/2017Stifel NicolausInitiated CoverageBuy$105.00High
5/22/2017WedbushReiterated RatingOutperform$112.00Low
4/4/2017WedbushReiterated RatingOutperform ➝ Outperform$100.00Low
3/16/2017Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
2/27/2017WedbushReiterated RatingOutperform ➝ Outperform$95.00N/A
2/13/2017Raymond JamesDowngradeOutperform ➝ Market PerformN/A
2/13/2017CitigroupDowngradeMarket Perform$60.00N/A
2/13/2017WedbushBoost Price TargetOutperform$85.00N/A
11/14/2016WedbushReiterated RatingOutperform$75.00N/A
11/3/2016WedbushReiterated RatingOutperform$63.00N/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 3 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
7/25/2021
  • 5 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/24/2021
  • 4 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
9/23/2021
  • 4 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Masimo logo
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $283.35
Low: $282.05
High: $285.15

50 Day Range

MA: $274.43
Low: $261.36
High: $286.12

52 Week Range

Now: $283.35
Low: $205.10
High: $288.27

Volume

221,187 shs

Average Volume

300,702 shs

Market Capitalization

$15.60 billion

P/E Ratio

73.41

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Masimo?

The following sell-side analysts have issued reports on Masimo in the last twelve months: Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for MASI.

What is the current price target for Masimo?

4 Wall Street analysts have set twelve-month price targets for Masimo in the last year. Their average twelve-month price target is $292.75, suggesting a possible upside of 3.6%. Robert W. Baird has the highest price target set, predicting MASI will reach $310.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $276.00 for Masimo in the next year.
View the latest price targets for MASI.

What is the current consensus analyst rating for Masimo?

Masimo currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MASI will outperform the market and that investors should add to their positions of Masimo.
View the latest ratings for MASI.

What other companies compete with Masimo?

How do I contact Masimo's investor relations team?

Masimo's physical mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider's listed phone number is (949) 297-7000 and its investor relations email address is [email protected] The official website for Masimo is www.masimo.com.